Literature DB >> 24304436

Epilepsy in TSC: certain etiology does not mean certain prognosis.

Aglaia Vignoli1, Francesca La Briola, Katherine Turner, Giulia Scornavacca, Valentina Chiesa, Elena Zambrelli, Ada Piazzini, Miriam Nella Savini, Rosa Maria Alfano, Maria Paola Canevini.   

Abstract

PURPOSE: Prevalence and long-term outcome of epilepsy in tuberous sclerosis complex (TSC) is reported to be variable, and the reasons for this variability are still controversial.
METHODS: We reviewed the clinical characteristics of patients with TSC who were regularly followed since 2000 at the San Paolo Multidisciplinary Tuberous Sclerosis Centre in Milan, Italy. From patient charts we collected data about age at epilepsy onset, seizure frequency and seizure type, history of infantile spasms (IS), epileptic syndrome, evolution to refractory epilepsy or to seizure freedom and/or medication freedom, electroencephalography (EEG) features, magnetic resonance imaging (MRI) findings, cognitive outcome, and genetic background. KEY
FINDINGS: Among the 160 subjects (120 adults and 40 children), 116 (72.5%) had epilepsy: 57 (35.6%) were seizure-free, and 59 (36.9%) had drug-resistant epilepsy. Most seizure-free patients had a focal epilepsy (89.5%), with 54.4% of them drug resistant for a period of their lives. Epilepsy onset in the first year of life with IS and/or focal seizures was characteristic of the drug-resistant group of patients, as well as cognitive impairment and TSC2 mutation (p < 0.05). A small group of patients (7 patients, 4.4%) experienced a seizure only once; all of them had normal cognition. SIGNIFICANCE: Although epilepsy management can be challenging in TSC, more than one third of patients had their seizures controlled: through monotherapy in 56% and by polytherapy in 32%. Moreover, 12% of the patients became seizure-free and were off medication. Identifying predictive features of epilepsy and cognitive outcome can ensure better management for patients with TSC and delineate genotype-phenotype correlations. Wiley Periodicals, Inc.
© 2013 International League Against Epilepsy.

Entities:  

Keywords:  Epilepsy; Outcome; Prognostic factors; Tuberous sclerosis complex

Mesh:

Substances:

Year:  2013        PMID: 24304436     DOI: 10.1111/epi.12430

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  25 in total

1.  Longitudinal changes in diffusion properties in white matter pathways of children with tuberous sclerosis complex.

Authors:  Fiona M Baumer; Jae W Song; Paul D Mitchell; Rudolph Pienaar; Mustafa Sahin; P Ellen Grant; Emi Takahashi
Journal:  Pediatr Neurol       Date:  2015-02-16       Impact factor: 3.372

2.  Factors affecting epilepsy prognosis in patients with tuberous sclerosis.

Authors:  Gülen Gül Mert; Şakir Altunbaşak; Özlem Hergüner; Faruk İncecik; Hilal Cansever Övetti; Neslihan Özcan; Duygu Kuşçu; İlker Ünal
Journal:  Childs Nerv Syst       Date:  2019-01-23       Impact factor: 1.475

3.  Impacting development in infants with tuberous sclerosis complex: Multidisciplinary research collaboration.

Authors:  Marian E Williams; Deborah A Pearson; Jamie K Capal; Anna W Byars; Donna S Murray; Robin Kissinger; Sarah E O'Kelley; Ellen Hanson; Nicole M Bing; Bridget Kent; Joyce Y Wu; Hope Northrup; E Martina Bebin; Mustafa Sahin; Darcy Krueger
Journal:  Am Psychol       Date:  2019-04

4.  Predictors of Drug-Resistant Epilepsy in Tuberous Sclerosis Complex.

Authors:  Anna Jeong; Jo Anne Nakagawa; Michael Wong
Journal:  J Child Neurol       Date:  2017-12       Impact factor: 1.987

5.  Influence of seizures on early development in tuberous sclerosis complex.

Authors:  Jamie K Capal; Beatriz Bernardino-Cuesta; Paul S Horn; Donna Murray; Anna Weber Byars; Nicole M Bing; Bridget Kent; Deborah A Pearson; Mustafa Sahin; Darcy A Krueger
Journal:  Epilepsy Behav       Date:  2017-04-28       Impact factor: 2.937

6.  Diagnostic features of tuberous sclerosis complex: case report and literature review.

Authors:  Sultan Abdulwadoud Alshoabi; Abdullgabbar M Hamid; Fahad H Alhazmi; Abdulaziz A Qurashi; Osamah M Abdulaal; Khaled M Aloufi; Tareef S Daqqaq
Journal:  Quant Imaging Med Surg       Date:  2022-01

Review 7.  Pharmacotherapy for Seizures in Tuberous Sclerosis Complex.

Authors:  Rima Nabbout; Mathieu Kuchenbuch; Catherine Chiron; Paolo Curatolo
Journal:  CNS Drugs       Date:  2021-08-21       Impact factor: 5.749

8.  Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference.

Authors:  Mustafa Sahin; Elizabeth P Henske; Brendan D Manning; Kevin C Ess; John J Bissler; Eric Klann; David J Kwiatkowski; Steven L Roberds; Alcino J Silva; Coryse St Hillaire-Clarke; Lisa R Young; Mark Zervas; Laura A Mamounas
Journal:  Pediatr Neurol       Date:  2016-04-02       Impact factor: 3.372

Review 9.  Genetic forms of epilepsies and other paroxysmal disorders.

Authors:  Heather E Olson; Annapurna Poduri; Phillip L Pearl
Journal:  Semin Neurol       Date:  2014-09-05       Impact factor: 3.420

Review 10.  Tuberous sclerosis complex: Five new things.

Authors:  David T Hsieh; Susan L Whiteway; Luis O Rohena; Elizabeth A Thiele
Journal:  Neurol Clin Pract       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.